Pediatrics
Showing 81-90 of 121 Results
-
Sneha Ramakrishna
Assistant Professor of Pediatrics (Hematology/Oncology)
BioSneha Ramakrishna obtained her B. A. from the University of Chicago and her M.D. from the Cleveland Clinic Lerner College of Medicine at Case Western Reserve University. In medical school, through the Howard Hughes Medical Research Scholar Award, she joined Dr. Crystal Mackall’s laboratory, where she designed and developed various GD2 CAR-Ts and tested them in preclinical models. During her residency training in Pediatrics at the Children’s Hospital of Philadelphia, she cared for some of the first patients treated with CD19 CAR T cells, learning the power of this therapy first-hand. During her fellowship in Pediatric Hematology/Oncology at the Johns Hopkins/National Cancer Institute combined program, she worked with Dr. Terry Fry. She evaluated the mechanism of CD22 CAR T cell relapse in patients by developing an antigen escape model and establishing a deeper understanding of the effects of antigen density on CAR-T phenotype, expansion, and persistence (Fry…Ramakrishna…Mackall Nat Med, 2018; Ramakrishna, et al., Clinical Cancer Research, 2019). Since arriving at Stanford, Dr. Ramakrishna leads an interdisciplinary team that designs, develops, and successfully implements a robust correlative science platform for our novel CAR-T therapies. Analyzing patient samples from our first-in-human GD2 CAR-T trial (NCT04196413) treating a universally fatal cancer, diffuse midline glioma (DMG), we identified that intracerebroventricular CAR-T administration correlates with enhanced pro-inflammatory cytokines and reduced immunosuppressive cell populations in cerebrospinal fluid as compared to intravenous CAR-T administration (Majzner*, Ramakrishna*, et al., Nature 2022 *co-first authors). Her research program evaluates unique sets of patient samples using novel single-cell immune profiling to identify the drivers of CAR-T success or failure. Building on these findings, her team assesses approaches to enhance CAR-T efficacy and translate these findings to the clinic.
Clinically, Dr. Ramakrishna cares for children with solid tumors and treats hematologic, solid, and brain tumor pediatric patients with CAR T cell therapies in the Cancer Cellular Therapies program. -
Brian Richter
Associate Director of Division Operations, Pediatrics - Hematology/Oncology
Current Role at StanfordAssociate Director of Division Operations, Department of Pediatrics, Division of Hematology, Oncology, Stem Cell Transplantation, & Regenerative Medicine
-
Katherine Jane Ryan
Clinical Assistant Professor, Pediatrics - Hematology & Oncology
Clinical Assistant Professor (By courtesy), Adult NeurologyCurrent Research and Scholarly InterestsDr. Katherine “Katie” Ryan is a pediatric neuro-oncologist whose research focuses on developing and translating cellular immunotherapies for children with malignant brain tumors. She leads the first-in-human trial of GPC2-directed CAR T cells for CNS Embryonal Tumors. As a member of Stanford Children’s world-renowned pediatric brain tumor team, she diagnoses and treats children with CNS tumors while advancing innovative trial design, intracerebroventricular delivery, and correlative science.
-
Raya Saab
Lindhard Family Professor of Pediatric Cancer Biology
BioI am a pediatric oncologist, and I primarily treat children who are diagnosed with soft tissue sarcomas including rhabdomyosarcoma, and children diagnosed with the eye tumor retinoblastoma, as well as children with other solid tumors.
I have two very different areas of primary research interest, both of which I pursue with passion. One focuses on global oncology, including clinical and research resource capacity building towards effective treatment and improving outcomes of children with cancer worldwide. I work with collaborators across the globe towards a common goal of improving access to diagnostic and clinical care, training of multidisciplinary teams, and building clinical resources and research capacity to develop context-informed approaches to improving cancer care and achieving better outcomes for children diagnosed with cancer irrespective of where they happen to live.
My parallel research interest, which is the focus of my laboratory, is understanding oncogenic signaling in pediatric soft tissue sarcomas, in an effort to clarify the driving biology and determinants of metastatic disease, to uncover novel targets for more effective treatment. We use preclinical in vitro and in vivo models, including murine and human cell lines, and mouse models of cancer. We have recently uncovered a paracrine role for rhabdomyosarcoma-secreted exosomes in impacting biology of stromal cells. Rhabdomyosarcoma-derived exosomes carry specific miRNA cargo that imparts an invasive and migratory phenotype on normal recipient fibroblasts, and proteomic analysis revealed specific and unique pathways relevant to the two different molecular rhabdomyosarcoma subtypes that are driven by distinct oncogenic pathways. We identified that the driver oncogene in fusion-positive rhabdomyosarcoma, PAX3-FOXO1, modulates exosome cargo to promote invasion, migration, and angiogenic properties, and identified specific microRNA and protein cargo acting as effectors of PAX3-FOXO1 exosome-mediated signaling, including modulation of oxidative stress response and cell survival signaling. Our ongoing work is focused on interrogating specific paracrine signaling pathways and molecular mechanisms of metastatic disease progression in rhabdomyosarcoma, for potential therapeutic targeting. -
Julien Sage
Elaine and John Chambers Professor of Pediatric Cancer and Professor of Genetics
Current Research and Scholarly InterestsWe investigate the mechanisms by which normal cells become tumor cells, and we combine genetics, genomics, and proteomics approaches to investigate the differences between the proliferative response in response to injury and the hyperproliferative phenotype of cancer cells and to identify novel therapeutic targets in cancer cells.
